TY -的T1 -中度和严重恶化加速身体活动减少慢性阻塞性肺病患者JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02110 -2017欧元六世- 51 - 1 SP - 1702110 AU Demeyer本意非盟- Costilla-Frias马科斯盟——Louvaris Zafeiris盟——Gimeno-Santos Elena盟——Tabberer玛吉AU -拉比诺维奇,罗伯特·a . AU -德容,科瑞娜AU - Polkey,迈克尔。非盟-霍普金森,尼古拉斯·s . AU - Karlsson Niklas AU -塞拉,Ignasi盟——Vogiatzis Ioannis盟——Troosters蒂埃里盟——Garcia-Aymerich Judith A2 - Y1 - 2018/01/01 UR - //www.qdcxjkg.com/content/51/1/1702110.abstract N2 -体育活动(PA)是一个有关测量结果在慢性阻塞性肺疾病(COPD)。PA普遍低,预后[1]。不幸的是,爸爸的决定因素及其随时间变化知之甚少[1]。PA的随着时间的推移逐渐下降以及肺功能和健康状况恶化[2]表明,巴勒斯坦权力机构下降可能是由于随着疾病的发展,特别是急性加重[3]。急性减少PA的报道都在严重发作需要住院治疗[4]和动态治疗急性加重(5、6)。持续减少PA已被证明出院后1个月[4]而PA几乎community-treated后返回到稳定水平恶化[6]。一项研究发现史的患者更快PA下降两个或两个以上的发作前的12个月内研究[5]。协会的分析没有调整混杂因素(如气流阻塞,症状负担)或外部变量影响PA(例如气候)。也可以认为,PA的大幅下降是由于低健康状况为基准。虽然爸爸是慢性阻塞性肺病患者的一个重要结果,对急性加重的作用在PA病人的经验。 Importantly, both the amount of activity and difficulties experienced during activity are integral to the concept of PA limitation [7]. The aim of the present analysis was to assess the association between the number and severity of exacerbations and changes in PA and PA experience.Exacerbations have a negative impact on long-term daily physical activity of COPD patients http://ow.ly/olGl30hkdMlWe are grateful for the input from the PROactive project ethics board, advisory board and patient input platform. The PROactive Consortium members are as follows: Nathalie Ivanoff (Almirall, Barcelona, Spain); Niklas Karlsson and Solange Corriol-Rohou (AstraZeneca AB, Gothenburg, Sweden); Ian Jarrod (British Lung Foundation, London, UK); Damijen Erzen (Boehringer Ingelheim, Nieder-Ingelheim, Germany); Mario Scuri and Roberta Montacchini (Chiesi Farmaceutici S.A., Parma, Italy); Paul McBride (Choice Healthcare Solutions, Hitchin, UK); Nadia Kamel (European Respiratory Society, Lausanne, Switzerland); Maggie Tabberer (GlaxoSmithKline, Uxbridge, UK); Thierry Troosters, Wim Janssens, Heleen Demeyer and Fabienne Dobbels (Katholieke Universiteit Leuven, Leuven, Belgium); Judith Garcia-Aymerich (ISGlobal, Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain); Pim de Boer (Netherlands Lung Foundation, Amersfoort, The Netherlands); Karoly Kulich (Novartis, Basel, Switzerland); Michael I. Polkey and Nick S. Hopkinson (Royal Brompton and Harefield NHS Foundation Trust, London, UK); Ioannis Vogiatzis (Thorax Research Foundation, Athens, Greece); Enkeleida Nikai (UCB, Brussels, Belgium); Thys van der Molen and Corina De Jong (University Medical Center, Groningen, The Netherlands); Roberto A. Rabinovich and Bill MacNee (University of Edinburgh, Edinburgh, UK); Milo A. Puhan and Anja Frei (University of Zurich, Zurich, Switzerland). ER -